Resistant Bacteria in Children in France

Study Overview
=================
Brief Summary
-----------------
This study is observational, multicenter and prospective study for surveillance of the use of new antibiotics in pediatrics for treated pediatrics infections due to multi-resistant bacteria

Detailed Description
-----------------
The main of this study is to evaluate the relevance of prescribing new antibiotics according to the antibiogram of the isolated bacteria or in the absence of bacteriological documentation As this is a surveillance study, the clinical and biological characteristics of the children included will be described.

Official Title
-----------------
National Surveillance of the Use of New Antibiotics in Pediatrics and Multi- Resistant Bacteria Involved in Pediatric Infections

Conditions
-----------------
Risk Factors, Infection Due to Resistant Bacteria, Multi-antibiotic Resistance, Antibiotic Prescription, Healing, Complications, Intensive Care Unit, Hospital Discharge, Outcome, Fatal

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Children under 18 years of age Hospitalized in France in a hospital center working with the ACTIV/GPIP network Treated with one or more of the following antibiotics: Colimycin (Colistimethate sodium) Cefiderocol Aztreonam in combination Ceftolozane-Tazobactam Ceftazidime-avibactam Meropenem/vaborbactam Imipenem/Relebactam Tigecycline Daptomycin Ceftaroline fosamil Tedizolid phosphate Fidaxomicin Ceftobiprole Dalbavancin In association with a documented infection performed by: Blood culture Normally sterile site Cerebrospinal fluid Pleural fluid Pleura Peritoneum Joint fluid Other Urine sampling if the bacteria was considered responsible for the infection (associated with a leukocyturia ≥10,0000) Respiratory specimens if the bacteria was considered responsible for the infection Sampling on material such as:Intubation probe, Orthopedic, Urological, Central Nervous System (CNS),.... Related to colonization with multidrug-resistant bacteria without documentation. Exclusion Criteria: Refusal of participation by the patient or his/her parent Medical history of mucoviscidosis

Ages Eligible for Study
-----------------
Maximum Age: 17 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Relevance of prescribing new antibiotics according to the antibiogram of the isolated bacteria or in the absence of bacteriological documentation | Type of new antibiotics prescribed for pediatrics infections caused by multi-resistant bacteria, and how are they used | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Describe Bacterial epidemiology of infections associated with prescription of new antibiotics | Characteristic of bacteria associated with prescription of new antibiotics | 1 year | 
| Identify Risks factors for multi-resistant bacteria | Type of conditions responsible of multi-resistant such as comorbidities, travel, previous hospitalization, previous antibiotherapy, | 1 year | 
| Discribe Context of drug Prescription | Number, type of departement involved and How antibiotics prescriptions are controlled and validated | 1 year | 
| Describe Associated Antibiotherapies | Number and type of drug association prescribed | 1 year | 
| Describe patients outcome | Proportion of patients clinically and bacteriologically recovered | 1 year |